{"id":"W2521045502","doi":"10.3324/haematol.2016.148924","title":"A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis","year":2016,"lang":"en","type":"article","venue":"Haematologica","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Jewish General Hospital; University of Toronto","funders":"National Cancer Institute; Gilead Sciences; European Hematology Association; American Society of Hematology","keywords":"Myelofibrosis; Medicine; Administration (probate law); Phase (matter); Phases of clinical research; Open label; Ruxolitinib; Internal medicine; Adverse effect; Clinical trial; Chemistry; Political science; Bone marrow","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005967862,0.000222867,0.0007945987,0.0001291762,0.00007041837,0.00002743896,0.0001708861,0.00009296211,0.0003992973],"category_scores_gemma":[0.0006359984,0.0001268474,0.00004903904,0.0002860152,0.00007194824,0.0001433835,0.0001191251,0.0000835176,0.0000676675],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007457449,"about_ca_system_score_gemma":0.0001769678,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004944747,"about_ca_topic_score_gemma":0.00009899439,"domain_scores_codex":[0.9979676,0.0002343417,0.0007047469,0.0004700338,0.0003564371,0.000266824],"domain_scores_gemma":[0.9986172,0.0004374604,0.0002817723,0.0003774659,0.0001701267,0.0001160306],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01258802,0.1239675,0.6931341,0.0002600153,0.0005017899,0.001590699,0.002605317,8.44848e-7,0.05406905,0.004247289,0.0008190935,0.1062163],"study_design_scores_gemma":[0.2124568,0.152447,0.4518912,0.002261725,0.0007120573,0.0006021943,0.002932763,0.0004000111,0.1739176,0.0011293,0.0004349177,0.0008143795],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9932799,0.0001047586,0.00004494976,0.001802027,0.00004647399,0.002446552,0.00002169431,0.00003693406,0.002216735],"genre_scores_gemma":[0.9959566,0.00004074506,0.00286839,0.0001359043,0.00001913819,0.0007472736,0.00001233571,0.00001635944,0.0002032395],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2412428,"threshold_uncertainty_score":0.5172687,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1801539089104497,"score_gpt":0.4582531616756482,"score_spread":0.2780992527651985,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}